BioAge Labs reported a gross margin of -580.46% and a net margin of -1,056.55% for the quarter ended Jun 2026. These financial ratios cover 12 quarters of results from Sep 2023 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Ratios | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||||
| Gross Margin | -219.02% | -478.57% | -496.30% | -504.84% | -374.06% | -580.46% | ||||||
| EBT Margin | -895.04% | -893.53% | -979.99% | -835.71% | -798.92% | -1,056.55% | ||||||
| EBIT Margin | -1,133.43% | -1,026.99% | -1,126.58% | -923.42% | -915.40% | -1,196.78% | ||||||
| EBITDA Margin | -1,133.43% | -1,026.99% | -1,126.58% | -923.42% | -915.40% | -1,196.78% | ||||||
| Operating Margin | -1,133.43% | -1,026.99% | -1,126.58% | -923.42% | -915.40% | -1,196.78% | ||||||
| Net Margin | -895.04% | -893.53% | -979.99% | -835.71% | -798.92% | -1,056.55% | ||||||
| FCF Margin | -1,225.98% | -834.49% | -782.18% | -921.47% | -868.40% | -799.18% | ||||||
| Efficiency | ||||||||||||
| Assets AverageAssets Avg. | 347.81M | 351.04M | 332.99M | 313.62M | 299.99M | 346.27M | 397.29M | |||||
| Invested CapitalInvested Cap. | -159.19M | 323.69M | 331.63M | 320.22M | 300.38M | 281.59M | 274.70M | 380.28M | 374.91M | |||
| Asset Utilization RatioAsset Util. | 0.00 | 0.01 | 0.02 | 0.03 | 0.03 | 0.03 | ||||||
| Leverage & Solvency | ||||||||||||
| Interest Coverage RatioInterest Cover | -4.11 | -5.31 | -10.53 | -34.47 | -63.79 | -79.50 | -64.49 | -123.24 | -155.30 | -308.95 | -650.64 | -0.03M |
| Debt Ratio | 0.55 | 0.03 | 0.02 | 0.02 | 0.02 | 0.01 | 0.01 | 0.00 | ||||
| Times Interest Earned | -4.11 | -5.31 | -10.53 | -34.47 | -63.79 | -79.50 | -64.49 | -123.24 | -155.30 | -308.95 | -650.64 | -0.03M |
| Valuation | ||||||||||||
| Price to EarningsP/E | -3.15 | -2.88 | -10.38 | -6.87 | -10.47 | -19.23 | -35.05 | -43.33 | ||||
| Price to SalesP/S | 92.90 | 61.39 | 102.63 | 160.70 | 280.06 | 457.77 | ||||||
| Price to BookP/B | 0.23 | 0.19 | 0.43 | 0.50 | 0.76 | 1.82 | 2.05 | 2.99 | ||||
| Enterprise Value | -261.81M | -292.24M | -263.34M | -242.30M | -155.31M | 213.53M | 250.01M | 495.91M | ||||
| EV to EBIT | 10.58 | 11.52 | 16.01 | 9.78 | 6.71 | -7.51 | -9.85 | -16.91 | ||||
| EV to EBITDA | 10.58 | 11.52 | 16.01 | 9.78 | 6.71 | -7.51 | -9.85 | -16.91 | ||||
| Market Capitalization | 72.69M | 62.11M | 134.80M | 148.06M | 210.80M | 494.63M | 776.32M | 1,121.99M | ||||
| Price to FCFP/FCF | -4.77 | -12.03 | -7.58 | -7.36 | -13.12 | -17.44 | -32.25 | -57.28 | ||||
| EV to FCF | 17.18 | 56.59 | 14.80 | 12.04 | 9.67 | -7.53 | -10.39 | -25.32 | ||||
| EV to CFO | 17.53 | 56.88 | 15.17 | 12.13 | 9.68 | -7.56 | -10.40 | -25.75 | ||||
| Return Ratios | ||||||||||||
| Return on Sales [ROS]ROS | -1,133.43% | -1,026.99% | -1,126.58% | -923.42% | -915.40% | -1,196.78% | ||||||
| Return on Capital Employed [ROCE]ROCE | -24.43% | -25.00% | -29.45% | -31.03% | -33.15% | -30.78% | -28.11% | |||||
| Return on Assets [ROA]ROA | -20.39% | -20.28% | -23.79% | -24.31% | -26.80% | -25.86% | -23.63% |